TB-500 (Ac-LKKTETQ) is a synthetic heptapeptide corresponding to amino acids 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid polypeptide first purified from thymic tissue. Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian systems, found in nearly every tissue except red blood cells, with particularly high concentrations in platelets, white blood cells, and wound fluid.
It is critical to understand that TB-500 and thymosin beta-4 are not the same molecule. TB-500 is a short synthetic fragment that contains the actin-binding motif of the parent protein. A fragment does not automatically have the same effects, pharmacokinetics, or safety profile as the whole. The vast majority of published research has been conducted on full-length thymosin beta-4 — not on the TB-500 fragment specifically.
As of 2025, there are zero published human clinical trials on TB-500. A Phase II trial on the parent protein thymosin beta-4 for venous stasis ulcers (NCT00832091) was completed in 2009, but results were never published — over 15 years later. This is a significant red flag in the scientific community. A 2024 study (Rahaman et al.) raised further questions by suggesting that TB-500's wound healing activity may come from a metabolite rather than the parent compound itself.
Thymosin beta-4's primary molecular function is regulation of the actin cytoskeleton. The following mechanisms have been identified primarily in preclinical research on the full-length parent protein:
Sequesters 40–50% of the cellular G-actin pool, maintaining reserves for rapid cytoskeletal reorganization
Promotes endothelial cell and progenitor cell migration to injury sites
Stimulates new blood vessel formation through endothelial cell proliferation and tube formation
Reduces inflammatory cytokines and decreases inflammatory cell infiltration
Decreases myofibroblast numbers, resulting in reduced scar formation
Reactivates embryonic cardiac progenitor cells in adult heart tissue (Bock-Marquette et al., 2004)
Critical caveat: A 2024 study (Rahaman et al.) found that TB-500's wound healing activity may actually come from a metabolite — acetyl-thymosin β4 (amino acid 1–17) — rather than the TB-500 fragment itself. This raises fundamental questions about whether the compound people are injecting is even the active agent.
Because TB-500 has zero human clinical data, contraindication profiles are derived entirely from its known mechanisms (particularly pro-angiogenic activity) and theoretical extrapolation from preclinical findings on the parent protein thymosin beta-4.
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| Active cancer or malignancy | HIGH | Pro-angiogenic activity may support tumor vascularization and growth. Thymosin beta-4 levels are elevated in some metastatic cancers. |
| History of hormone-sensitive cancers | HIGH | Angiogenesis and cell migration promotion pose theoretical risk for dormant cancer reactivation |
| Pregnancy / breastfeeding | HIGH | No reproductive toxicology data exists for TB-500 or thymosin beta-4 in human pregnancy |
| Proliferative retinopathies | HIGH | Pro-angiogenic activity is specifically contraindicated in conditions where pathological blood vessel growth occurs |
| Cardiovascular conditions | MODERATE | Angiogenesis and vasodilation may cause blood pressure changes. Complex interactions with cardiac medications possible. |
| Autoimmune conditions | MODERATE | Immune-modulating properties may unpredictably affect autoimmune disease activity |
| Current immunosuppressive therapy | MODERATE | Immune pathway modulation may cause unpredictable interactions |
| Anticoagulant therapy | MODERATE | Angiogenic activity may interact with bleeding risk. Thymosin beta-4 is concentrated in platelets. |
| Preclinical animal safety | LOW (preclinical) | No adverse effects observed in standard animal toxicity studies for thymosin beta-4 |
| Human safety data | UNKNOWN | Zero published human clinical trials for TB-500. Unpublished Phase II trial results for parent protein are a red flag. |
FDA: TB-500 is classified as a Category 2 bulk drug substance — a "Substance with Safety Concerns" that is prohibited from being compounded for human use. The FDA cites significant safety risks including potential for immune reactions and lack of human safety data.
WADA: Classified under S0: Non-Approved Substances on the Prohibited List. Banned at all times, in and out of competition. Detection methods exist for both equine and human doping control.
DEA: TB-500 is not a DEA-scheduled substance. Possession is not illegal. However, it cannot be legally prescribed, compounded, or sold as a drug, food, or dietary supplement.
Important distinction: The research on thymosin beta-4 (the full 43-amino acid parent protein) is extensive. The research on TB-500 (the 7-amino acid synthetic fragment) is almost nonexistent. These are different molecules with potentially different properties. Marketing materials that conflate the two are misleading.
Answer these compound-specific screening questions to evaluate whether TB-500 research is appropriate given your profile. Enter your email to receive your results.
Enter your email to receive your full TB-500 readiness report with personalized safety notes: